For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Silver Creek Pharmaceuticals, Inc.

USPTO Granted Patents = 10

EPO Patents = 3

Forward Citations = 26

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Matthew D Onsum (10 out of 15 patents)

Laura D J Antipov (5 out of 5 patents)

Shawdee Eshghi (5 out of 5 patents)

4. Kristopher M Kuchenbecker (5 out of 5 patents)

5. Bjorn L Millard (5 out of 5 patents)

6. Andrea D Nickerson (5 out of 5 patents)

7. Timothy R Stowe (5 out of 5 patents)

8. Thomas Joseph Wickham (5 out of 15 patents)

9. Brian Harms (5 out of 11 patents)

10. Birgit Schoeberl (5 out of 16 patents)

11. Bryan Linggi (5 out of 9 patents)

12. Byron DeLaBarre (5 out of 9 patents)

13. Yan Zhang (5 out of 14 patents)

14. Ulrik Bjerl Nielsen (5 out of 24 patents)

15. Shaun M Lippow (3 out of 12 patents)

10 patents: Sort by Forward Citations

1. 12122819 - Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant (2024-10-22),

2. 11879002 - Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof (2024-01-23),

3. 11814443 - Bi-specific fusion proteins (2023-11-14),

4. 11673970 - Bi-specific fusion proteins (2023-06-13),

5. 11155593 - Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5 (2021-10-26),

6. 10988547 - Bi-specific fusion proteins (2021-04-27),

7. 10858450 - Bi-specific fusion proteins (2020-12-08),

8. 10633425 - Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5 (2020-04-28),

9. 10407512 - Bi-specific fusion proteins (2019-09-10),

10. 10040840 - Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue (2018-08-07),

Silver Creek Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to developing innovative therapies to address unmet medical needs in oncology and rare diseases. Leveraging cutting-edge research and advanced drug development technologies, we strive to make a meaningful impact on patients' lives. Our pipeline includes promising drug candidates with the potential to transform the treatment landscape and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

10 Patents

#430 in San Francisco, CA

#6,897 in California

#29,016 in US

#54,349 in the World

San Francisco, CA, United States of America

Silver Creek Pharmaceuticals, Inc.

Forward Citations = 26

15 inventors:

Matthew D Onsum (10 out of 15 patents)

Laura D J Antipov (5 out of 5 patents)

Shawdee Eshghi (5 out of 5 patents)

4. Kristopher M Kuchenbecker (5 out of 5 patents)

5. Bjorn L Millard (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…